



Press release

Cantargia AB
556791-6019
August 22, 2016

Cantargia raises kSEK 250 through exercise of warrants

Cantargia AB ("Cantargia") has today announced that the company's former CEO, Agneta Svedberg, has exercised 1,250 warrants of series 2011/2016. The exercise of the warrants will raise SEK 250,212.50 for Cantargia.

Agneta Svedberg has exercised her full holding of 1,250 warrants, which gave her the right to subscribe for 37 shares per warrant at a price of SEK 5.41 per share. The exercise of the warrants will result in a dilution of around 0.3 per cent for existing shareholders. Upon registration with the Swedish Companies Registration Office, the total number of outstanding shares of Cantargia will be 17,679,384. The share capital will be SEK 1,414,350.72.

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail: goran.forsberg@cantargia.com
Certified Adviser: Sedermera Fondkommission

This constitutes information that Cantargia is required to publish under the EU's Market Abuse Regulation. The information was submitted for publication through the above contact person at 8:30 (CEST) on August 22, 2016.

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor associated protein "IL1RAP", in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The company has selected a product candidate for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.

Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company's Certified Adviser. More information about Cantargia is available at <http://www.cantargia.com>.